382 related articles for article (PubMed ID: 25897458)
1. Alemtuzumab (LEMTRADA) and multiple sclerosis. Biased evaluation, evidence of serious risks.
Prescrire Int; 2015 Mar; 24(158):69. PubMed ID: 25897458
[TBL] [Abstract][Full Text] [Related]
2. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab treatment of multiple sclerosis.
Coles AJ
Semin Neurol; 2013 Feb; 33(1):66-73. PubMed ID: 23709214
[TBL] [Abstract][Full Text] [Related]
4. The outlook for alemtuzumab in multiple sclerosis.
Williams T; Coles A; Azzopardi L
BioDrugs; 2013 Jun; 27(3):181-9. PubMed ID: 23558379
[TBL] [Abstract][Full Text] [Related]
5. Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.
Lambert C; Dubois B; Dive D; Lysandropoulos A; Selleslag D; Vanopdenbosch L; Van Pesch V; Vanwijmeersch B; Janssens A
Acta Neurol Belg; 2018 Mar; 118(1):7-11. PubMed ID: 29380254
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
Hersh CM; Cohen JA
Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.
Ruck T; Bittner S; Wiendl H; Meuth SG
Int J Mol Sci; 2015 Jul; 16(7):16414-39. PubMed ID: 26204829
[TBL] [Abstract][Full Text] [Related]
8. Current evaluation of alemtuzumab in multiple sclerosis.
Coyle PK
Expert Opin Biol Ther; 2014 Jan; 14(1):127-35. PubMed ID: 24289293
[TBL] [Abstract][Full Text] [Related]
9. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management.
Decallonne B; Bartholomé E; Delvaux V; D'haeseleer M; El Sankari S; Seeldrayers P; Van Wijmeersch B; Daumerie C
Acta Neurol Belg; 2018 Jun; 118(2):153-159. PubMed ID: 29372482
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab and multiple sclerosis: therapeutic application.
Minagar A; Alexander JS; Sahraian MA; Zivadinov R
Expert Opin Biol Ther; 2010 Mar; 10(3):421-9. PubMed ID: 20095876
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.
Berger T; Elovaara I; Fredrikson S; McGuigan C; Moiola L; Myhr KM; Oreja-Guevara C; Stoliarov I; Zettl UK
CNS Drugs; 2017 Jan; 31(1):33-50. PubMed ID: 27882532
[TBL] [Abstract][Full Text] [Related]
12. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
Sørensen PS
J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
[TBL] [Abstract][Full Text] [Related]
13. [Alemtuzumab, a monoclonal antibody against CD52: hopes and fears].
Mori M
Brain Nerve; 2014 Oct; 66(10):1179-89. PubMed ID: 25296872
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to Management.
Mahzari M; Arnaout A; Freedman MS
Can J Neurol Sci; 2015 Sep; 42(5):284-91. PubMed ID: 25990097
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Skoromets A; Stolyarov I; Bass A; Sullivan H; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Neurology; 2012 Apr; 78(14):1069-78. PubMed ID: 22442431
[TBL] [Abstract][Full Text] [Related]
16. Mode of action and clinical studies with alemtuzumab.
Jones JL; Coles AJ
Exp Neurol; 2014 Dec; 262 Pt A():37-43. PubMed ID: 24792641
[TBL] [Abstract][Full Text] [Related]
17. Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis.
Buonomo AR; Saccà F; Zappulo E; De Zottis F; Lanzillo R; Gentile I; Carotenuto A; Borgia G; Russo CV
Mult Scler Relat Disord; 2019 Jan; 27():44-45. PubMed ID: 30316174
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab (TYSABRI) and multiple sclerosis. With longer follow-up: even more toxic than suspected.
Prescrire Int; 2015 Mar; 24(158):65-7. PubMed ID: 25897454
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab in multiple sclerosis: an update.
Gross RH; Krieger S
Neurodegener Dis Manag; 2015; 5(3):225-32. PubMed ID: 26107321
[TBL] [Abstract][Full Text] [Related]
20. Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis--Report of Two Cases.
Rau D; Lang M; Harth A; Naumann M; Weber F; Tumani H; Bayas A
Int J Mol Sci; 2015 Jun; 16(7):14669-76. PubMed ID: 26132570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
